All In Biotech

Drug Trial Radar · NCT02781883

Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML

A Phase IIa, Open-label, Clinical Trial to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of BP1001 (a Liposomal Grb2 Antisense Oligonucleotide) in Combination With Venetoclax Plus Decitabine in Patients With AML Who Are Ineligible for Intensive Induction Therapy

Last checked: Nov 19, 2026Latest source record: Mar 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

108

Planned (sponsor's estimate)

Start

May 2016

Primary completion

Dec 2027

Study completion Dec 2028

Sponsor

Lead sponsor
Bio-Path Holdings, Inc.Industry
Sponsor type
Industry
First posted
May 25, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objectives of this study are to assess: (1) whether the combination of BP1001 plus venetoclax plus decitabine provides greater efficacy (Complete Remission \[CR\], Complete Remission with incomplete hematologic recovery \[CRi\], Complete Remission with partial hematologic recovery \[CRh\], than venetoclax plus decitabine alone (by historical comparison) in participants with untreated AML that cannot or elect not to be treated with more intensive chemotherapy; (2) whether BP1001-based treatment provides greater efficacy (CR, CRi, CRh) than intensive chemotherapy (by historical comparison) in participants with refractory/relapsed AML.

Conditions

  • Acute Myeloid Leukemia (AML)

Interventions

  • BP1001 in combination with Ventoclax plus decitabineDrug

    BP1001 in combination with Ventoclax plus decitabine

  • BP1001 plus decitabineDrug

    BP1001 plus decitabine in ventoclax intolerant or resistant subjects

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Assessment of efficacy in untreated AML subjects by bone marrow aspirate or biopsyTime frame: 180 days
  2. Assessment of efficacy in refractory/relapsed AML subjects by bone marrow aspirate or biopsyTime frame: 180 days

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • UCLA Medical Center

    Los Angeles, California · Recruiting

  • Georgia Cancer Center at Augusta University

    Augusta, Georgia · Recruiting

  • University of Kansas Cancer Center

    Fairway, Kansas · Recruiting

  • New Jersey Hematology Oncology Associates

    Brick, New Jersey · Terminated

  • Laura & Isaac Pe lmutter Cancer Center at NYU Langone Health

    New York, New York · Recruiting

  • Weill Cornell Medical College - New York - Presbyterian Hospital

    New York, New York · Recruiting

  • University of Texas M.D. Anderson Cancer Center

    Houston, Texas · Recruiting

  • Baylor Scott & White Research Institute

    Temple, Texas · Terminated

  • West Virginia University/Mary Babb Randolph Cancer Center

    Morgantown, West Virginia · Terminated

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.